Eu Cosmetic Cpsr Pif Consultant

Scope and evidence must be confirmed before any paid tests or filings.

An EU cosmetic CPSR/PIF consultant should first decide what the product is, who will be legally responsible and whether existing evidence is fit for purpose. Commissioning a laboratory package or filing a CPNP notification before those decisions can lock a business into the wrong regulatory route.

This is a pre-execution decision guide, not a promise of product approval. The relevant legal framework is Regulation (EC) No 1223/2009; a consultant is not automatically the responsible person or the qualified safety assessor.

Decide whether the cosmetic route applies

Start with the intended function, the part of the body contacted, the mode of action, the formula and every consumer-facing claim. Products primarily used to clean, perfume, change appearance, protect or keep the relevant external body surfaces or teeth/oral mucosa in good condition may fall within the cosmetics definition. A treatment, disease-prevention or disinfectant claim can change the analysis; wording alone cannot make an otherwise non-cosmetic product a cosmetic.

The Commission treats borderline classification case by case. Where the facts remain inconclusive, obtain a documented classification analysis and, where appropriate, approach the competent national authority before committing to a cosmetic CPSR.

Initial facts	Provisional route	Decision gate	Do not assume
External skin-care product with cosmetic claims and known formula	Potential cosmetics route	Check the complete formulation, exposure, restrictions and RP	That a category name proves classification or safety
“Treats eczema”, “kills germs” or similar therapeutic/biocidal positioning	Borderline: medicinal/biocidal/device analysis first	Review intended purpose, evidence, mechanism and relevant sector law	That removing a claim automatically resolves classification
Product whose intended contact or principal purpose falls outside Article 2	Other product-law assessment	Identify the actual regime before buying a CPSR	That every personal-care product needs a cosmetic CPSR
Cosmetic concept but unfinished formula, unclear supplier or packaging	Conditional cosmetics route; evidence not ready	Freeze the product definition and close blocking inputs	That a preliminary ingredient check replaces a final safety assessment

Establish the responsible-person and product identity

Identify the product and business model: EU-made under an EU brand, imported from a third country, contract-manufactured, or rebranded. Article 4 determines the responsible-person route; an EU-established responsible person must exist for each cosmetic placed on the EU market. For imports the importer is generally the responsible person for the specific product, subject to the Regulation’s written-mandate arrangements. Rebranding or modifying a product may transfer responsible-person obligations to a distributor. Where several importers independently place the same imported cosmetic on the EU market, assess Article 4(5) for each importer and any written designation it makes; one importer’s arrangement does not automatically cover the others.

Map who controls the exact formula, signs the assessor engagement, grants access to supplier data, holds the PIF at the labelled address and submits/maintains the CPNP notification. A consulting contract alone does not appoint an RP; verify the mandate, acceptance and actual access rights.

Gap analysis: which missing evidence changes the route?

Rank each gap by its effect on route choice, assessor feasibility and market readiness. A gap is not automatically a request for a new test; start with existing, traceable data and ask the qualified assessor what remains necessary.

Evidence requested	Question it resolves	If missing	Safe next action
Intended use, claims, exposure sites, audience	Cosmetic classification and exposure scenario	Classification cannot be confidently closed	Document claims and assess borderline regime first
Exact qualitative/quantitative formula, raw-material identities and specifications	Ingredient restrictions, toxicological review and formula identity	Safety assessor lacks critical inputs	Request supplier composition/specifications under confidentiality safeguards
Relevant stability, microbiology and packaging-compatibility information	Finished-product safety and suitability over use	Evidence adequacy cannot be decided generically	Have assessor define a risk-based evidence or testing plan
Manufacture/GMP statement, claims substantiation, label artwork	PIF completeness and consistency of claims/label	Dossier may remain incomplete despite a CPSR	Assign document owners and close distinct PIF sections
RP identity, PIF access location, market list, CPNP status	Legal accountability and pre-market notification	Market-entry readiness unverified	Confirm RP agreement, labels and notification route

Reuse evidence only within its proven scope

Reuse is a documented scientific judgment, not a discount based on similar product names. Existing ingredient toxicology, supplier specifications or studies may inform several SKUs if provenance, substance identity, relevant concentrations and exposure assumptions remain valid. The qualified assessor must determine whether the finished-product evidence and Part B conclusions cover the exact variant.

CosIng and its ingredient glossary are useful research tools, not lists authorising every ingredient. Screen the applicable Annexes and amendments as of the intended placing-on-market date; Regulation (EU) 2026/909 is one reason a previously acceptable formula deserves a current review.

Change	What may be reusable	What needs a new decision
New fragrance or colour variant	Base-formula data and shared manufacturing evidence	Allergen/restricted-substance screen, exposure and assessor coverage
New jar, pump or contact material	Ingredient profiles and some stability history	Compatibility, contamination and use-dependent exposure
New age group, application area or frequency	Underlying ingredient references	Different exposure, warnings and suitability
New medical-sounding claim or material formula revision	Some historical test records	Regulatory classification first; revised safety/claim substantiation

For substances affected by Regulation (EU) 2026/909, distinguish its entry into force on 18 May 2026 from transitional restrictions in specific Annex entries, including 1 January 2027 for placing non-compliant products on the market and 1 July 2028 for making them available, where specified. These dates are not a general grace period for other obligations: check the substance, product type and entry. Some Annex III entries instead set 1 August 2028 as the date after which non-compliant products must no longer be made available; read the applicable entry rather than applying 1 July to every ingredient.

Sequence the decisions before commissioning work

Use stage gates; each stage produces a decision record rather than an automatic laboratory order.

Gate 1 — Scope: Freeze intended use, claims, presentation and borderline risks; select the defensible product-law route.
Gate 2 — Accountability: Identify the Article 4 responsible person, supplier-data access and PIF location.
Gate 3 — Evidence sufficiency: Screen formula restrictions, flag nanomaterials if relevant, map Annex I information and decide what studies the assessor needs.
Gate 4 — Expert sign-off: Have an appropriately qualified safety assessor prepare/sign the CPSR Part B; complete PIF, GMP and claims/label checks.
Gate 5 — Market readiness: Confirm RP-controlled CPNP notification under Article 13 before placing on the market; evaluate any separate Article 16 nanomaterial obligations and later changes.

The PIF must remain readily accessible at the RP address indicated on the label and be retained for 10 years after the last batch was placed on the market. CPNP notification is free and is not a regulatory approval or substitute for a compliant product. Follow applicable national label-language rules.

If Article 16 applies to a nanomaterial, a separate notification is generally due six months before the product is placed on the market; statutory exceptions apply. Assess this at launch planning, as an Article 13 CPNP notification does not replace it. Article 16 normally excludes nanomaterials used as colourants, UV filters or preservatives regulated under Article 14, unless expressly specified; the six-month rule also does not apply to nanomaterials in products complying with the relevant Annex III requirements. Confirm the particular ingredient and use before relying on an exception.

What the consultant should deliver

Ask for a written classification memo with alternative regimes considered; a product/variant identity register; an RP responsibility map; a red/amber/green evidence-gap register with reasons; a data-reuse and testing decision log; and a launch-gate plan with named document owners. These are consulting deliverables, not substitutes for the signed scientific safety assessment.

Check the proposed assessor’s qualifications under Article 10(2), how supplier-confidential formula data are accessed, who can update the PIF, and how regulatory amendments, complaints, incidents and formula changes trigger reassessment. No consultancy can legitimately promise automatic CPNP “approval”, universal test exemptions or that one CPSR covers materially different products.

Hand off execution without duplicating it

Once the strategy and missing-data decisions are settled, the operational dossier and notification work belong to dedicated delivery workflows: CPSR/PIF preparation services; the scientific evaluation and assessor engagement belong to cosmetic safety-assessment service; the notification submission itself belongs to CPNP notification consulting. The consultant should specify precisely when each hand-off occurs.

A go/no-go decision depends on the exact formula, finished-product evidence, target users, claims, packaging and responsible-person arrangements. Without those facts, neither market eligibility nor the amount of additional testing can be concluded.

Questions before appointing an EU cosmetic CPSR/PIF consultant

Can my non-EU manufacturer appoint a consultant and skip an EU responsible person?

No. An EU-established responsible person is required for an EU-market cosmetic. The consultant may be a separate adviser; confirm who legally accepts the RP role and who holds the PIF.

Does an existing CPSR cover a second fragrance or package size?

Not automatically. Compare formula, allergens, exposure, packaging and assessor scope. The assessor must determine whether an update or separate assessment is necessary.

Should I order a challenge test and stability testing before the first consultation?

Not automatically. Provide the formula, preservation strategy, packaging and existing studies first. The qualified assessor should identify evidence gaps and justify any additional testing.

Can CPNP notification cure missing PIF documents?

No. CPNP is a notification tool, not an approval. The legal duties to ensure safety, hold the PIF and complete the CPSR remain independent.

What if the label says “antibacterial” or “eczema relief”?

Treat it as a classification trigger. Evaluate intended purpose, mechanism, presentation and the potentially applicable biocidal or medicinal framework before assuming a cosmetic route.